Pancreatic Ductal Adenocarcinoma Pipeline 2025: Pioneering Clinical Developments by 80+ Global Leaders - DelveInsight, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines

Key companies in pancreatic ductal adenocarcinoma market include Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, and Tarveda Therapeutics.
With Pancreatic Ductal Adenocarcinoma (PDAC) reaching epidemic levels globally and contributing to comorbidities such as diabetes, cardiovascular disease, and other cancers, there is an increasing demand for safer and more effective therapies. According to DelveInsight, the PDAC pipeline consists of over 80 pharmaceutical and biotech companies developing more than 80 therapeutic candidates across various clinical and preclinical stages, highlighting significant innovation and commitment to addressing this major public health challenge.

DelveInsight's report, "Pancreatic Ductal Adenocarcinoma Pipeline Insight 2025," offers a comprehensive and strategic analysis of the R&D landscape, including clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. It serves as an essential resource for researchers, healthcare investors, and decision-makers, providing insights into the evolving PDAC therapeutics market and the breakthroughs shaping its future.

Explore the Cutting-Edge Landscape of Pancreatic Ductal Adenocarcinoma Drug Development [https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

*
DelveInsight's Pancreatic Ductal Adenocarcinoma (PDAC) pipeline report highlights a dynamic landscape with over 80 active companies developing more than 80 investigational therapies for PDAC treatment.

*
In April 2025, Nelson Yee announced a Phase II clinical trial to assess the safety and efficacy of liposomal irinotecan (nal-IRI) combined with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI) in patients with locally advanced pancreatic cancer (LAPC).

*
In the same month, InxMed (Shanghai) Co. Ltd initiated a multicenter, open-label, single-arm Phase Ib/II study comprising two phases: a dose confirmation phase to determine the recommended Phase II dose (RP2D) for IN10018 plus standard chemotherapy (albumin-bound paclitaxel and gemcitabine) and IN10018 plus KN046 plus standard chemotherapy in advanced pancreatic cancer patients, followed by a dose expansion phase to further evaluate safety and antitumor activity of these combinations.

*
Key PDAC companies actively developing new therapies include Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others, all aiming to improve the PDAC treatment landscape.

*
Promising PDAC pipeline therapies under development include Onvansertib, Nadunolimab, Zimberelimab, among others.

Pancreatic Ductal Adenocarcinoma Overview:

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a 5-year survival rate below 10%. Most patients are diagnosed at a stage when the disease is unresectable, locally advanced, or metastatic. The poor prognosis is largely due to the complex and multifactorial nature of PDAC. Early detection is difficult, as there are no simple screening methods, and symptoms usually appear only after the cancer has progressed and spread to other organs. Treating PDAC is particularly challenging because of genetic and cellular complexities. The high mutation burden in pancreatic tumors leads to genomic instability, which drives tumor progression and contributes to resistance to therapies.

Download the Pancreatic Ductal Adenocarcinoma sample report to know in detail about the Pancreatic Ductal Adenocarcinoma treatment market [https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Pancreatic Ductal Adenocarcinoma Pipeline Analysis

The Pancreatic Ductal Adenocarcinoma pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Pancreatic Ductal Adenocarcinoma Market.

*
Categorizes Pancreatic Ductal Adenocarcinoma therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Pancreatic Ductal Adenocarcinoma drugs under development based on:

*
Stage of development

*
Pancreatic Ductal Adenocarcinoma Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Pancreatic Ductal Adenocarcinoma Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Pancreatic Ductal Adenocarcinoma Licensing agreements

*
Funding and investment activities supporting future Pancreatic Ductal Adenocarcinoma market advancement.

Unlock key insights into emerging Pancreatic Ductal Adenocarcinoma therapies and market strategies here: https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Pancreatic Ductal Adenocarcinoma Emerging Drugs

*
Onvansertib: Cardiff Oncology

Onvansertib is an oral, highly selective PLK1 inhibitor under investigation in clinical trials in combination with standard-of-care therapies for diseases such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These studies, along with the broader development strategy, are designed to target tumor vulnerabilities, address treatment resistance, and potentially deliver improved clinical outcomes compared to current standard treatments.

*
Nadunolimab: Cantargia

Nadunolimab is a humanized, fucose-free monoclonal antibody developed by Cantargia for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic cancer. As a first-in-class anti-IL1RAP antibody, Nadunolimab is being evaluated in combination with standard chemotherapy or checkpoint inhibitors across five Phase I/II clinical trials, mainly targeting PDAC and NSCLC. Its mechanism involves antibody-dependent cellular cytotoxicity (ADCC) and the inhibition of IL-1 and IL-1 signaling, helping to modulate the immune-suppressive tumor microenvironment and overcome chemotherapy resistance.

*
Zimberelimab: Arcus Biosciences

Zimberelimab is a PD-1-targeting monoclonal antibody that enhances T-cell-mediated antitumor activity. Arcus has licensed zimberelimab to develop precision combination therapies. Its most advanced program is a Phase 2 trial evaluating first-line metastatic non-small cell lung cancer, where zimberelimab is combined with domvanalimab (an anti-TIGIT antibody) and etrumadenant (a dual A2a/A2b adenosine receptor antagonist). In addition, zimberelimab is being studied as a monotherapy in a Phase 1b trial for biomarker-selected cancers that currently lack approved anti-PD-1 therapies, aiming to provide innovative treatment options for patients with unmet needs.

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment

Pancreatic Ductal Adenocarcinoma Assessment by Product Type

- Mono

- Combination

- Mono/Combination

Pancreatic Ductal Adenocarcinoma By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Download sample pages to get an in-depth assessment of the emerging Pancreatic Ductal Adenocarcinoma therapies and key Pancreatic Ductal Adenocarcinoma companies: https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Report Introduction

2. Executive Summary

3. Pancreatic Ductal Adenocarcinoma Current Treatment Patterns

4. Pancreatic Ductal Adenocarcinoma - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Pancreatic Ductal Adenocarcinoma Late-Stage Products (Phase-III)

7. Pancreatic Ductal Adenocarcinoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pancreatic Ductal Adenocarcinoma Discontinued Products

13. Pancreatic Ductal Adenocarcinoma Product Profiles

14. Pancreatic Ductal Adenocarcinoma Key Companies

15. Pancreatic Ductal Adenocarcinoma Key Products

16. Dormant and Discontinued Products

17. Pancreatic Ductal Adenocarcinoma Unmet Needs

18. Pancreatic Ductal Adenocarcinoma Future Perspectives

19. Pancreatic Ductal Adenocarcinoma Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the Pancreatic Ductal Adenocarcinoma pipeline reports offerings: https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pancreatic-ductal-adenocarcinoma-pipeline-2025-pioneering-clinical-developments-by-80-global-leaders-delveinsight-signalchem-lifesciences-bristolmyers-squibb-astrazeneca-revolution-medicines]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.